Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shahnaz Mahdavifar

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Immunological Methods|September 8, 2004
Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometryKarina Godoy-Ramirez, Kristina Franck, Shahnaz Mahdavifar, et al.
Clinical and Vaccine Immunology : CVI|October 30, 2009
Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401Simani Gaseitsiwe, Davide Valentini, Shahnaz Mahdavifar, et al.
Journal of Immunological Methods|September 4, 2007
Validation of peptide epitope microarray experiments and extraction of quality dataTatjana Nahtman, Alexander Jernberg, Shahnaz Mahdavifar, et al.
Journal of Immunological Methods|January 24, 2009
Identification and testing of control peptides for antigen microarraysYen Ngo, Reza Advani, Davide Valentini, et al.
Plos One|April 18, 2014
Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV statusLena Pérez-Bercoff, Davide Valentini, Simani Gaseitsiwe, et al.
Plos One|December 10, 2008
Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosisSimani Gaseitsiwe, Davide Valentini, Shahnaz Mahdavifar, et al.
Clinical and Vaccine Immunology : CVI|February 20, 2009
Major histocompatibility complex class II molecule-human immunodeficiency virus peptide analysis using a microarray chipSimani Gaseitsiwe, Davide Valentini, Raija Ahmed, et al.
Vaccine|February 21, 2017
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trialsMaria Norrby, Timo Vesikari, Lars Lindqvist, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Immunological Methods|September 8, 2004
Optimum culture conditions for specific and nonspecific activation of whole blood and PBMC for intracellular cytokine assessment by flow cytometryKarina Godoy-Ramirez, Kristina Franck, Shahnaz Mahdavifar, et al.
Clinical and Vaccine Immunology : CVI|October 30, 2009
Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401Simani Gaseitsiwe, Davide Valentini, Shahnaz Mahdavifar, et al.
Journal of Immunological Methods|September 4, 2007
Validation of peptide epitope microarray experiments and extraction of quality dataTatjana Nahtman, Alexander Jernberg, Shahnaz Mahdavifar, et al.
Journal of Immunological Methods|January 24, 2009
Identification and testing of control peptides for antigen microarraysYen Ngo, Reza Advani, Davide Valentini, et al.
Plos One|April 18, 2014
Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV statusLena Pérez-Bercoff, Davide Valentini, Simani Gaseitsiwe, et al.
Plos One|December 10, 2008
Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosisSimani Gaseitsiwe, Davide Valentini, Shahnaz Mahdavifar, et al.
Clinical and Vaccine Immunology : CVI|February 20, 2009
Major histocompatibility complex class II molecule-human immunodeficiency virus peptide analysis using a microarray chipSimani Gaseitsiwe, Davide Valentini, Raija Ahmed, et al.
Vaccine|February 21, 2017
Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trialsMaria Norrby, Timo Vesikari, Lars Lindqvist, et al.
Pageof 1